艾美赛珠单抗(Emicizumab) - 药物靶点：F10 x factor IXa_在研适应症：凝血因子缺乏症，血友病A，获得性因子 VIII缺乏症_专利_临床

概要

基本信息

药物类型

双特异性抗体

别名

Anti-factor IXa anti-factor X humanized bispecific antibody、Emicizumab (Genetical Recombination)、Emicizumab (genetical recombination) (JAN)

+ [14]

靶点

F10 x factor IXa

作用方式

抑制剂

作用机制

F10抑制剂(凝血因子X抑制剂)、factor IXa抑制剂(激活型凝血因子IX抑制剂)

治疗领域

遗传病与畸形血液及淋巴系统疾病其他疾病

在研适应症

凝血因子缺乏症血友病A获得性因子 VIII缺乏症+ [1]

非在研适应症-

原研机构

Chugai Pharmaceutical Co., Ltd.

在研机构

Hoffmann-La Roche, Inc.F. Hoffmann-La Roche Ltd.

罗氏（中国）投资有限公司

+ [7]

非在研机构-

权益机构

Chugai Pharmaceutical Co., Ltd.

JW PHARMACEUTICAL Corp.

最高研发阶段批准上市

首次获批日期

美国 (2017-11-16),

血友病A

最高研发阶段(中国)批准上市

特殊审评孤儿药 (美国)、优先审评 (中国)、孤儿药 (日本)、孤儿药 (韩国)、孤儿药 (澳大利亚)、优先审评 (澳大利亚)、突破性疗法 (美国)

登录后查看时间轴

结构/序列

Sequence Code 5386H

来源: *****

Sequence Code 5425H

来源: *****

Sequence Code 5467L

来源: *****

关联

63

项与艾美赛珠单抗相关的临床试验

NCT06938659

/ Not yet recruiting临床2/3期IIT

Comparison of Low Dose Emicizumab and Low Dose Factor VIII as a Prophylaxis in Hemophilia A Patients- a Randomized Control Trial'

Low dose factor VIII prophylaxis is practiced around the world. Role of standard dose Emicizumab prophylaxis is well established. Emicizumab is an expensive drug. Standard dose Emicizumab prophylaxis is very expensive for hemophilia A patients and troublesome for government to ensure continuous supply. This study intends to compare low dose Factor VIII prophylaxis with low dose Emicizumab prophylaxis and compare whether low dose Emicizumab is as effective as low dose Factor VIII prophylaxis. So, it is possible to continue prophylaxis program in hemophilia A patients with a cost-effective way in our country without risking the patient health. Moreover, Emicizumab prophylaxis reduces the chance of developing inhibitor to Factor VIII and it is convenient for administration due to less frequent and subcutaneous administration. 20 severe hemophilia A patients will be selected randomly from interested patients for this study. 6 patients with inhibitor will be randomized in Low dose Emicizumab with Inhibitor group (I) and rest 14 will be randomized by block randomization in Low dose Emicizumab (without inhibitor-WI) and low dose Factor VIII group at 4:10 ratio. Initial loading dose will be given and the participants will be followed up for 6 months. At the end of the study Annualized bleeding rate (ABR), Annualized joint bleeding rate (AJBR), Annualized spontaneous bleeding rate (ASBR), APTT will be compared among the groups. Inhibitor to factor VIII will also be evaluated after six months in Factor VIII group.

开始日期2025-06-01

申办/合作机构

Dhaka Medical College

NCT04563520

/ Recruiting临床3期IIT

APCC and Emicizumab Safety Study in Congenital Hemophilia a Patients with Inhibitors (SAFE Study: Safety of APCC Following Emicizumab Prophylaxis)

The purpose of the aPCC-emicizumab safety study is to investigate the hemostatic efficacy as measured by thrombin generation, of a low personalized dose of aPCC (FEIBA) in children and adults with hemophilia A and inhibitors on emicizumab prophylaxis.

开始日期2025-04-01

申办/合作机构

Emory University

[+1]

CTRI/2024/08/071826

/ Recruiting临床4期IIT

Outcome of Emicizumab Prophylaxis in Patients of Haemophilia A with or without Inhibitor An Early Experience from A Tertiary Care Hospital From Eastern India - NIL

开始日期2024-08-15

申办/合作机构-

100 项与艾美赛珠单抗相关的临床结果

登录后查看更多信息

100 项与艾美赛珠单抗相关的转化医学

登录后查看更多信息

100 项与艾美赛珠单抗相关的专利（医药）

登录后查看更多信息

673

项与艾美赛珠单抗相关的文献（医药）

2025-12-31·JOURNAL OF MEDICAL ECONOMICS

Systematic review of cost-effectiveness modelling studies for haemophilia

Review

作者: Meier, Niklaus ; Ammann, Daniel ; Schwenkglenks, Matthias ; Probst, Jano ; Pletscher, Mark

AIMS:

Haemophilia is a rare genetic disease that hinders blood clotting. We aimed to review model-based cost-effectiveness analyses (CEAs) of haemophilia treatments, describe the sources of clinical evidence used by these CEAs, summarize the reported cost-effectiveness of different treatment strategies, and assess the quality and risk of bias.

METHODS:

We conducted a systematic literature review of model-based CEAs of haemophilia treatments by searching databases, the Tufts Medical Center CEA registry, and grey literature. We summarized and qualitatively synthesized the approaches and results of the included CEAs, without a meta-analysis due the diversity of the studies.

RESULTS:

32 eligible studies were performed in 12 countries and reported 53 pairwise comparisons. Most studies analysed patients with haemophilia A rather than haemophilia B. Comparisons of prophylactic versus on-demand treatment indicated that prophylaxis may not be cost-effective, but there was no clear consensus. Emicizumab was generally cost-effective compared with clotting factor treatments and was always dominant for patients with inhibitors. Immune tolerance induction following a Malmö protocol was found to be cost-effective compared to bypassing agents, while there was no consensus for the other protocols. Gene therapies as well as treatment with extended half-life coagulation factors were always cost-effective over their comparators. Studies were highly heterogenous regarding their time horizons, model structures, the inclusion of bleeding-related mortality and quality-of-life impacts. This heterogeneity limited the comparability of the studies. 19 of the 32 included studies received industry funding, which may have biased their results.

LIMITATIONS:

It was not possible to perform a quantitative synthesis of the results due to the heterogeneity of the underlying studies.

CONCLUSION:

Differences in results between previous CEAs may have been driven by heterogeneity in modelling approaches, clinical input data, and potential funding biases. A more consistent evidence base and modelling approach would enhance the comparability between CEAs.

2025-06-01·JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Diffusion dimensionality modeling of subcutaneous/intramuscular absorption of antibodies and long-acting injectables

Article

作者: Ramanathan, Murali ; Krzyzanski, Wojciech

To evaluate the role of diffusion process dimensionality in drug absorption following subcutaneous or intramuscular administration. The diffusion dimensionality model is based on analytical solutions of the 1-, 2- or 3-dimensional diffusion equations for a bolus input linked to a central compartment with first-order elimination. The model equations were reparameterized to contain three parameters for the time needed for the drug diffusion from the administration site, drug absorption into the central compartment, and the elimination rate constant. The diffusion dimensionality models were challenged with previously published subcutaneous absorption data for 13 antibody drugs and insulin lispro, and the long-acting injectable antipsychotic drugs: subcutaneous Perseris™, intramuscular Invega Sustenna®, Risperdal Consta®, and olanzapine. The Bayesian information criterion was used for model selection. The solution to the diffusion equation for a bolus dose administration is strongly dependent on the number of dimensions. The maximal concentration is lowest for the 3-dimensional diffusion equation. The pharmacokinetic profiles of all 13 antibodies were satisfactorily approximated by a diffusion dimensionality model. Three antibodies (CNTO5825, ACE910 and ustekinumab) were best described by the 2-dimensional diffusion equation. The 2- and 3-dimensional diffusion equations were equivalent for ABT981, guselkumab, adalimumab, nemolizumab, omalizumab, and secukinumab. Golimumab, DX2930, AMG139, and mepolizumab were best described by the 3-dimensional diffusion equation. All the long-acting antipsychotic dosage forms except Risperdal Consta were modeled satisfactorily. Diffusion dimensionality models are a parsimonious and effective approach for modeling drug absorption profiles of subcutaneously and intramuscularly administered small molecule and protein drugs and their dosage forms.

2025-05-01·JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Accurate evaluation of factor VIII activity of efanesoctocog alfa in the presence of emicizumab

Article

作者: Marquez, Elizabeth ; Pipe, Steven W ; Young, Guy ; Dargaud, Yesim ; Huisman, Albert ; Quehenberger, Peter ; Sexton, Edison ; Van Dievoet, Marie-Astrid ; Nougier, Christophe ; Guery, Eve-Anne ; Hermans, Cedric ; Pouplard, Claire ; Pabinger, Ingrid ; Schutgens, Roger E G

BACKGROUND:

Efanesoctocog is a B-domain-deleted, Fc-fusion factor (F)VIII linked to the D'D3 domain of von Willebrand factor and 2 XTEN polypeptides, designed for an ultra-extended half-life for prophylaxis in hemophilia A, but also aiding in managing acute bleeding or surgery in patients on long-term emicizumab. However, no current laboratory method accurately measures FVIII levels in the presence of emicizumab.

OBJECTIVES:

To test whether the bovine chromogenic FVIII assay, specifically calibrated for efanesoctocog, could provide an accurate assessment of efanesoctocog activity.

METHODS:

Seven centers across 5 countries received 12 plasma samples to measure in triplicate using 2 calibration methods across 3 independent days. Samples (n = 6) contained either only efanesoctocog (FVIII activity [FVIII:C]= 5 to 150 IU/dL), or efanesoctocog (FVIII:C = 5 to 150 IU/dL) in combination with emicizumab (50 μg/mL; n = 5). One sample contained efanesoctocog (FVIII:C = 50 IU/dL) and a high dose of emicizumab (80 μg/mL); another sample contained efanesoctocog (FVIII:C = 50 IU/dL) with a low dose of emicizumab (20 μg/mL). Each center used its own analyzers, along with their usual reagents.

RESULTS:

Chromogenic assay (CSA) calibrated with standard calibrators highly overestimates FVIII:C. However, specific calibration with efanesoctocog enabled accurate measurement of FVIII:C, with low inter- and intra-laboratory variability, and no interference from emicizumab. All CSA reagents used in the study demonstrated low variability across different laboratories (interlaboratory coefficient of variation ranges between 9% and 20%).

CONCLUSION:

Specific calibration of the FVIII CSA using efanesoctocog and bovine reagents allows for accurate measurement of FVIII:C in patients receiving efanesoctocog, even in the presence of emicizumab.

417

项与艾美赛珠单抗相关的新闻（医药）

2025-05-08

·米内网

【瞩目】南京正大天晴猛攻$50亿大品种

精彩内容5月8日，CDE官网显示，南京正大天晴制药的艾美赛珠单抗注射液2个受理号的临床申请获受理，在此之前，公司该产品已有1个受理号的临床申请在审评审批中。米内网数据显示，艾美赛珠单抗在2024年全球销售额超过50亿美元，中国三大终端六大市场（统计范围见文末）销售额超过1亿元。艾美赛珠单抗是由罗氏研发，用于预防因缺乏凝血因子VIII而引起的出血事件的药物，2018年获批进入中国市场。近年中国三大终端六大市场艾美赛珠单抗销售情况（单位：万元）来源：米内网格局数据库艾美赛珠单抗在近年市场规模持续扩容，2024年全球销售额超过50亿美元，中国三大终端六大市场销售额超过1亿元，同比增长4.04%。米内网数据显示，艾美赛珠单抗注射液在国内仅有罗氏拥有生产批文，南京正大天晴制药则是首家申报临床的生物类似药。来源：米内网一键检索截至目前，南京正大天晴制药在生物药领域暂无产品获批上市。今年3月，公司的NTB003注射液提交临床申请获CDE受理，目前在审评审批中，是公司申报的首款生物药1类新药。来源：CDE官网、米内网数据库注：米内网《中国三大终端六大市场药品竞争格局》，统计范围是：城市公立医院和县级公立医院、城市社区中心和乡镇卫生院、城市实体药店和网上药店，不含民营医院、私人诊所、村卫生室，不含县乡村药店；上述销售额以产品在终端的平均零售价计算。如有疏漏，欢迎指正！免责声明：本文仅作医药信息传播分享，并不构成投资或决策建议。本文为原创稿件，转载文章或引用数据请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092●温馨提示●因为微信公众号修改了推送规则，最近很多读者反映没有及时看到推文。把米内网设为“星标”，就能每天与我们不见不散啦，具体操作如下：【分享、点赞、在看】点一点不失联哦

生物类似药

2025-05-01

·赛柏蓝

最新！销售额TOP100药品（附名单）

编者按：本文来自Insight数据库；赛柏蓝授权转载，编辑凯西ADC 与双抗的崛起、GLP-1的跨界扩张、国产创新药的突破等，共同勾勒出全球医药领域的新面貌。一如往年，Insight 数据库根据财报整理了2024年药品销售额TOP100榜单。从金额来看，上榜的药品销售额门槛和2023年一样，仍然保持在17亿美元量级。其中，销售额超过50亿美元的药物有35款，超过100亿美元的超级重磅炸弹有12款。012024年度TOP100药品销售榜单（亿美元）02总体概况2024 年有 12 款药品销售额突破百亿美元。帕博利珠单抗以 294.82 亿美元蝉联「药王」，其适应症扩展至 40 余项，覆盖肺癌、黑色素瘤等核心癌种，占据大量肿瘤免疫治疗市场份额。司美格鲁肽凭借 Ozempic（降糖注射版）、Rybelsus（降糖口服版）和 Wegovy（减重版）三大版本，极限追赶，位列第二。整体来看，相较于去年，今年的榜单中虽然有 83 个是老面孔，但末 20 席迎来了大换血。泽布替尼（百济）、艾加莫德（Argenx/再鼎）、尼塞维单抗（赛诺菲/阿斯利康）、替妥木单抗（安进），还有大冢制药的托伐普坦、阿立哌唑、依匹哌唑等多款新药入围。从企业角度来看，强生、罗氏、阿斯利康在 TOP100 榜单中占据最多，都达到了 11 席。诺华、礼来、辉瑞紧随其后。各大药企进入 TOP100 药品销售榜单的药品数量截图来源：多个药品为合作开发，故总和＞100从药物类型来看，化药和单抗仍然占到了大半。化药的药品销售收入达到 2006.93 亿美元，单抗销售收入达 1778.35 亿美元。TOP100 药品销售榜单中不同药物类型数量03ADC 和双抗下一代肿瘤疗法的「双子星」据公开资料显示，2024 年全球 ADC 市场规模近 130 亿美元。尽管 TOP100 榜单里只有 2 款 ADC，分别是第一三共/阿斯利康的德曲妥珠单抗和罗氏的恩美曲妥珠单抗，但这两款产品的销售表现均不俗，一共拿下了 57.14 亿美元。恩美曲妥珠单抗于 2013 年 2 月首次获 FDA 批准上市，用于治疗曾接受过曲妥珠单抗和紫杉烷类化疗治疗的 HER2 阳性转移性乳腺癌患者。同时这也是全球首个获批单药治疗实体瘤的 ADC 药物。近两年来，该药也持续入选 TOP100 榜单。德曲妥珠单抗在获批上市以后，第一三共和阿斯利康对 DXd 管线们铺开了广泛而差异化的临床布局，撒下了腾飞的「火种」。随着各项适应症的陆续登场，2023 年该药首次进入 TOP100 榜单，并一举超过恩美曲妥珠单抗，从「跟随者」成为了「颠覆者」。24 年又有新突破，全球销售额达 34.5 亿美元，同比增加 37.83%。但该药的潜力并不仅限于此，和 K 药联用一线治疗 HER2 过表达 NSCLC 的 III 期临床试验（NCT06899126）正如火如荼地开展，有望成为新的治疗标准。类似的，24 年双抗市场规模同样也接近 130 亿美元。而纵观 TOP100 榜单，入围的总共有 3 款双抗产品，分别是罗氏的艾美赛珠单抗、法瑞西单抗以及诺华的奥法妥木单抗。这三款产品总共贡献了 127.05 亿美元，占到了全球双抗市场规模的 97% 左右。04增速狂飙超 40% 增长的「现象级药物」这一年，TOP100 榜单中有 12 款药品的同比增长率超过了 40%，更有 2 款产品凭借超高增速加入百亿美元分子俱乐部：替尔泊肽在 2024 年销售额高达 164.66 亿美元，同比大增 208.41%，同时还获 FDA 批准用于治疗中重度阻塞性睡眠呼吸暂停（OSA）合并肥胖症成人患者，未来增长空间不可小觑。利生奇珠单抗 24 年实现了 117.18 亿美元的销售额，同比增长 50.95%，成为艾伯维继阿达木单抗之后的下一个百亿美元分子。赛诺菲与阿斯利康联合开发，用于呼吸道合胞病毒感染的尼塞维单抗在增速表现上也十分亮眼，增幅达到 205%，首次入围 TOP100 榜单。值得一提的是，百济神州研发的 BTK 抑制剂泽布替尼全年销售额达 26.44 亿美元，同比增长 103.40%，成为首个跻身 TOP100 榜单的国产创新药。END内容沟通：郑瑶（13810174402）

抗体药物偶联物财报上市批准引进/卖出

2025-04-28

·空之客

【医苑观畴】2025年一季度海外药企进展更新：罗氏ROG

1整体表现虎落平阳的肿瘤一哥罗氏，医药板块的业绩在去年上半年一波起色后，又陷于环比停滞，因而市值也就只能在$250b左右徘徊不前。全年指引基本维持不变，收入增长预计在mid single digit、EPS增长也就high single digit，这就很欧洲。2已上市产品过去两年独撑业绩危局的眼科双抗Vabysmo渐有触顶之态，好在Phesgo勉强顶上来，但整个产品梯队中已然看不到大额增量的来源，不过好在LOE的一堆抗体药物已经出清得差不多了，因此整体看起来还能保持同比微涨的趋势。肿瘤板块在彻底挥别老一代传奇重磅品种之后，新生代虽有表现，但仍难达到续写辉煌的水平。HER2复方抗体Phesgo的市场转化率已经爬升到47%，距离公司宣称的50%目标已所剩无几，单季接近CHF600m，应该有在中国通过谈判纳入医保目录的贡献，LTM累计CHF1.9b；ADC药物Polivy在1L DLBCL的份额也爬升至31%，单季CHF358m、LTM累计CHF1.2b；而两款CD20/CD3双抗在末线依然无甚起色，单季合计迟迟无法突破CHF100m，即使距离公司宣称的末线峰值销售额CHF700m也遥遥无期。自免板块最核心的仍是Ocrelizumab，皮下制剂看起来正在兑现预期，持续推动销售额爬坡，单季CHF1.8b、LTM累计CHF6.9b，而且4月已拿到J-code，此外皮下制剂有50%新患此前并没有用过Ocrelizumab，这都验证着皮下制剂确有可能大幅延长Ocrelizumab的生命周期。公司维持着峰值销售额CHF8.5b的预期，其中皮下制剂占CHF2b。前两年事实上ROG业绩的扛把子，终于也开始放缓：眼科双抗Faricimab环比下滑，单季CHF1.2b、LTM累计CHF4.0b，主要是美国市场新患的市场份额已经高达60%、以及基金会赠药的减少，只能靠欧洲和刚进医保的中国市场，公司预计年内还能维持20%左右同比增长；而血友病双抗Emicizumab因美国渠道商采购节奏的影响出现环比回落，欧洲也基本失去增速，只有国际市场还有70%同比增速；SMA药物Risdiplam连续多个季度走平，基因治疗Elevidys获批后短暂单季破CHF100m后又迅速滑落。3在研管线就凭现在这个核心管线进展图，已经有点难以想象ROG曾经是肿瘤霸主，而今的研发重点则迁移到心血管代谢、神经、自免等方向，甚至季报里公然出现了“Roche's commitment to become a leader in CVRM”这种违背祖宗遗训之词。既然都CVRM leader了，任何减肥靶点都不能错过，于是这个季度就以$1.65b upfront + $3.6b milestone拿下了Zealand的Amylin类似物Petrelintide，这是继Carmot之后在减肥领域FoMo心态的又一次淋漓尽致的体现。接下来是神经板块的两个重要管线数据读出：TfR1介导的透脑抗体Trontinemab，公布了1/2期临床中期分析数据，给药28周后1.8和3.6mpk剂量组的Aβ PET转阴比例为65%和81%，并且ARIA发生率较低；α-synuclein单抗Prasinezumab公布了2b期临床PADOVA试验的左旋多巴胺治疗人群的结果，虽然整个试验主要终点未达到显著性，但这个subgroup勉强显著，HR=0.79（0.63, 0.99）、p=0.0431，维持着这个靶点继续走下去的希望。然后是自免板块，在TCE和CAR-T风起云涌的背景下，朴实无华的CD20单抗Obinutuzumab在NEJM上发表了三期临床REGENCY试验结果，给药76周后，Obinutuzumab联合SOC（霉酚酸酯+糖皮质激素）与单纯SOC对比，肾脏缓解率CRR为46.4% vs 33.1%，p=0.0232，sBLA已提交，PDUFA在今年10月；不过另一边Ocrelizumab高剂量组却在治疗RMS的三期临床MUSETTE试验中未能达到主要临床终点。此外还有一个重要管线，二代血友病双抗NXT007进入三期临床（一代Hemlibra年销售额高达CHF4.6b），在NVO的Mim8三期临床已经读出的背景下，ROG也势必要维护在这一细分适应症的地位。那么肿瘤板块呢？主要就看TIGIT单抗Tiragolumab从失败走向失败，联用PD1治疗nsq-NSCLC的SKYSCRAPER-06因未能显著改善OS而被正式终止，联用PD1治疗食管癌的SKYSCRAPER-07也被终止，连同过去几个季度的各种坏消息，TIGIT目前也只剩HCC等少数几个瘤种明面上还在开发……除此以外，值得关注的进展还包括：Susvimo获得FDA批准治疗DME，Glofitamab联用GemOx获得欧洲批准治疗2L+ DLBCL，Mosunetuzumab联用Polivy治疗2L+ DLBCL的三期临床SUNMO试验积极结果公布等。Roche总给人一种值得进商学院教科书的感觉，其兴也肿瘤、其落也肿瘤，最强大的能力铸就了曾经的辉煌、也可能恰恰成为眼下的桎梏。如今的Roche，从巅峰落下后短短几年时间，无论是业绩支柱、还是重点研发方向，几乎已经看不到多少当年在肿瘤领域叱咤风云的影子，不知道在心血管代谢、神经、免疫等领域的救赎，是否还能复现Genentech时代的威仪？罗氏ROG往期季报分析：【医苑观畴】主流技术方向谁说了算：2022年上半年全球大药企核心产品管线进展总览【医苑观畴】主流技术方向谁说了算：2022年下半年全球大药企核心产品管线进展总览【医苑观畴】2023年上半年全球大药企核心进展总览【医苑观畴】2024年二季度海外药企进展更新：罗氏ROG【医苑观畴】2024年三季度海外药企进展更新：罗氏ROG

抗体药物偶联物引进/卖出

100 项与艾美赛珠单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10821	艾美赛珠单抗	B02BX06	DB13923

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
凝血因子缺乏症	日本	Chugai Pharmaceutical Co., Ltd.	2018-03-23
血友病A	美国	Genentech, Inc.	2017-11-16

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
获得性因子 VIII缺乏症	临床2期	奥地利	Hoffmann-La Roche, Inc.	2021-03-23
获得性因子 VIII缺乏症	临床2期	德国	Hoffmann-La Roche, Inc.	2021-03-23
血管性血友病3型	临床1期	美国	Genentech, Inc.	2022-11-01
血友病	临床1期	中国	罗氏（中国）投资有限公司	2018-03-12
血友病	临床1期	中国	F. Hoffmann-La Roche Ltd.	2018-03-12

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASH2024	N/A	血友病A	-	Emicizumab	餘觸繭鹽範觸夢簾憲廠(襯鏇願醖網艱選簾齋齋) = 齋觸鬱蓋構衊簾簾餘鏇網壓簾繭艱淵願壓醖壓 (鑰選鏇襯繭膚衊齋顧糧, 1.1) 更多	-	2024-12-09
ASH2024	N/A	-	-	Emicizumab	蓋選壓齋積構醖鏇繭選(襯鏇簾簾鹽壓餘繭醖糧) = 蓋壓鑰窪網淵餘齋簾夢築構網蓋窪鹹餘願願夢 (壓鑰積衊構範鹽淵繭衊 ) 更多	-	2024-12-08
NCT04431726 (HAVEN 7, ASH2024)	临床3期	血友病A FVIII inhibitors	55	Emicizumab	醖窪願艱襯餘顧顧憲鑰(膚鏇蓋願糧鬱製願獵鏇) = 衊餘觸蓋憲艱繭襯鹽願蓋壓淵齋範簾製鑰範觸 (醖觸範鏇蓋鏇繭壓鏇構 )	积极	2024-12-08
				Factor VIII	醖窪願艱襯餘顧顧憲鑰(膚鏇蓋願糧鬱製願獵鏇) = 積構壓鹹選觸遞淵艱遞蓋壓淵齋範簾製鑰範觸 (醖觸範鏇蓋鏇繭壓鏇構 )
ASH2024	N/A	血友病A	-	Emicizumab	夢鏇鬱鬱積壓衊襯鑰壓(艱醖夢繭鏇壓淵鹽範鏇) = 鑰鑰遞壓鑰構淵淵選淵鏇夢鏇鹹膚鑰製製獵構 (糧觸鬱網憲鹹憲窪繭廠 )	-	2024-12-07
				Comparators	夢鏇鬱鬱積壓衊襯鑰壓(艱醖夢繭鏇壓淵鹽範鏇) = 選憲鹽膚憲繭簾艱鏇鏇鏇夢鏇鹹膚鑰製製獵構 (糧觸鬱網憲鹹憲窪繭廠 )
EHA2024	N/A	-	25	octocog alfa	鹽壓鬱壓淵壓繭鹽鹽廠(願壓淵憲餘齋淵繭遞窪) = 糧遞觸艱選夢顧鑰醖膚構獵齋淵壓觸範蓋簾製 (鬱繭鏇願簾簾窪鑰衊淵, 38)	-	2024-05-14
				emicizumab	鹽壓鬱壓淵壓繭鹽鹽廠(願壓淵憲餘齋淵繭遞窪) = 衊憲淵醖餘憲襯襯鑰鑰構獵齋淵壓觸範蓋簾製 (鬱繭鏇願簾簾窪鑰衊淵, 9)
EHA2024	N/A	血友病A	16	Emicizumab	醖遞鏇顧獵艱襯衊鑰壓(積糧製獵憲鏇顧蓋鏇糧) = 醖遞膚窪製顧糧艱製憲願衊顧淵齋齋積壓艱簾 (齋膚齋積願獵簾觸蓋積 )	不佳	2024-05-14
				FVIII replacement	醖遞鏇顧獵艱襯衊鑰壓(積糧製獵憲鏇顧蓋鏇糧) = 遞衊艱顧遞壓醖鬱選壓願衊顧淵齋齋積壓艱簾 (齋膚齋積願獵簾觸蓋積 )
P11-5.023 (AAN2024)	N/A	获得性因子 VIII缺乏症 Factor VIII level \| Factor VIII inhibitor level	-	Emicizumab	壓窪選選壓糧築鹹衊廠(網鹽顧積淵齋廠遞艱製) = Apixaban was initiated for secondary prevention with no ischemic or hemorrhagic events at 3 and 6 month follow ups 膚衊選積觸壓淵簾襯構 (範構衊衊願鹹衊壓築積 ) 更多	不佳	2024-04-09
NCT03191799 (STASEY, Pubmed \| TH Open) 人工标引	临床3期	血友病A	56	Emicizumab prophylaxis with additional hemostatic medication	襯淵廠網衊築鏇鑰窪獵(淵糧淵衊獵蓋窪觸壓鑰) = 網衊壓顧淵鏇獵願製憲鹹遞鏇顧艱糧衊艱鹽醖 (網壓觸觸糧鹹鹽築鏇醖 ) 更多	积极	2024-01-12
				Emicizumab prophylaxis without additional hemostatic medication	襯淵廠網衊築鏇鑰窪獵(淵糧淵衊獵蓋窪觸壓鑰) = 鑰鑰糧衊構膚築鹽齋鬱鹹遞鏇顧艱糧衊艱鹽醖 (網壓觸觸糧鹹鹽築鏇醖 )
ASH2023	N/A	血友病A	-	Emicizumab	製糧繭醖遞醖範膚醖鏇(範鏇淵膚壓夢壓簾構顧) = 窪夢糧選廠糧餘蓋蓋積艱簾壓窪選遞築壓糧鹽 (鹽獵窪鏇憲願製鹽觸繭 )	-	2023-12-11
				Efanesoctocog alfa	製糧繭醖遞醖範膚醖鏇(範鏇淵膚壓夢壓簾構顧) = 膚鏇範餘簾廠觸壓夢鏇艱簾壓窪選遞築壓糧鹽 (鹽獵窪鏇憲願製鹽觸繭 )
ASH2023	N/A	血友病A	127	Emicizumab prophylaxis	齋窪淵艱築膚窪製醖憲(鑰齋夢襯鹽鬱願艱淵鏇) = 願廠簾憲夢淵膚鹽選糧齋壓觸構願構觸選艱窪 (築積願願積膚糧壓簾願 ) 更多	-	2023-12-10